Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

A 63-year-old woman underwent a complex eight-hour surgery at Pune's Jupiter Hospital, where doctors removed a rare, benign ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

Borderline personality disorder may be the reason behind your severe mood changes. Know what to do about this mental health ...

Johnson & Johnson said on Monday it would buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Attention Deficit Hyperactivity Disorder ADHD is a condition that affects behaviour causing restlessness difficulty ...

Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

Viral TikToker Baylen Dupree talks with PEOPLE exclusively about wanting to educate viewers about what it's like to have ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of ...

Intra-Cellular Therapies’ performance in the stock market has been impressive, especially considering the broader market environment. The company’s stock is up +52.51% year-to-date (YTD), a remarkable ...